Ampliphi Biosciences (APHB) Sees Large Volume Increase

Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) saw an uptick in trading volume on Monday . 6,647 shares traded hands during mid-day trading, a decline of 99% from the previous session’s volume of 481,151 shares.The stock last traded at $0.34 and had previously closed at $0.35.

Separately, HC Wainwright restated a “buy” rating and set a $3.50 price target on shares of Ampliphi Biosciences in a research note on Tuesday, March 26th.

Ampliphi Biosciences (NYSEAMERICAN:APHB) last released its quarterly earnings results on Monday, March 25th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.07).

ILLEGAL ACTIVITY WARNING: This piece of content was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.chaffeybreeze.com/2019/04/15/ampliphi-biosciences-aphb-sees-large-volume-increase.html.

About Ampliphi Biosciences (NYSEAMERICAN:APHB)

AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus infections; and AB-PA01 for the treatment of pseudomonas aeruginosa infections.

Recommended Story: Analyst Ratings Trading

Receive News & Ratings for Ampliphi Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampliphi Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.